Selenium is essential, but it is not a nutrient for which more is automatically better. A new dose-response meta-analysis places an important marker at 200 µg per day: at and above that supplemental dose, blood lipids shifted in several directions, not all of them favorable.
That amount deserves attention because 200 µg is a common high-dose supplement strength. It is also the dose now being tested in a major Scandinavian heart-failure trial. Those facts do not make 200 µg a recommended daily intake. They make it a research dose worth examining carefully.
What the review studied
The systematic review, published in Nutrition Reviews, identified 27 randomized controlled trials in adults. The trials included healthy participants, pregnant participants and people with specific health conditions. Researchers searched four major databases from their start dates through January 11, 2025.
Rather than asking only whether selenium changed cholesterol on average, the authors modeled how the response varied with the administered dose and with the blood selenium concentration reached by the end of a trial. They examined total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides.
The abstract does not report the combined number of participants or the size of the lipid changes. That limits what can responsibly be said about clinical importance. The review identifies the direction and shape of the dose-response relationship; it does not establish that a particular dose will cause a heart attack or prevent one.
What happened around 200 µg per day
At selenium doses of 200 µg/day or higher, the analysis found lower HDL cholesterol, lower LDL cholesterol and higher triglycerides.
That is a mixed pattern. Lower LDL is generally considered favorable, while lower HDL and higher triglycerides can be unfavorable. Calling every observed change “worse cholesterol” would therefore be inaccurate. The authors nevertheless judged the overall high-dose pattern adverse, particularly when considering the triglyceride and HDL findings together.
The blood-level analysis pointed in a similar direction. End-of-trial selenium concentrations above approximately 150 µg/L were associated with higher triglycerides and LDL cholesterol and lower HDL cholesterol. This was a relationship across trials, not a diagnostic threshold proving that every individual above 150 µg/L will have an adverse response.
Form, starting level and duration mattered
Selenium is not one uniform intervention. The meta-analysis found stronger adverse associations with inorganic selenium than with organic forms. It also found that people starting with the lowest selenium intake could show beneficial lipid changes instead. Taken together, most of the dose-response curves were U-shaped: too little and too much may both be less favorable than an adequate middle range.
The adverse pattern was stronger in healthy participants than in participants with health conditions or pregnancy. It was also more apparent in interventions lasting more than 3 months. Among European populations, the strongest adverse pattern appeared above 300 µg/day.
These subgroup results should not be read as precise personal cutoffs. They come from comparisons among trials with different populations, selenium forms and durations. They do, however, argue against treating selenium status, supplement form and dose as interchangeable details.
Why 200 µg is already a high-dose question
European regulators set the adult tolerable upper intake level at 255 µg/day, counting food and supplements together. A 200 µg tablet therefore uses most of that allowance before dietary selenium is included. Other authorities use different limits, but all distinguish nutritional adequacy from high-dose supplementation.
The meta-analysis did not test one branded product, and its conclusions should not be transferred to every preparation as if the formulations were identical. Its clearest practical message is narrower: a 200 or 300 µg supplement is not simply a stronger version of a normal dietary intake.
What KiSel-10 can and cannot tell us
The Swedish KiSel-10 trial is often cited in discussions of 200 µg selenium. It randomized 443 adults aged 70–88 to placebo or a combination of 200 µg/day of selenium yeast plus 200 mg/day of coenzyme Q10 for four years. Over a median 5.2 years, cardiovascular mortality was 5.9% in the active-treatment group and 12.6% in the placebo group.
That result is notable, but it does not isolate selenium. The active group received two substances together, with no selenium-only or Q10-only arm. The participants also came from one Swedish municipality, and the study was much smaller than a modern cardiovascular outcomes trial. Pharma Nord supplied the active products and placebos and was listed as an industry collaborator in the trial registration.
Later KiSel-10 analyses and long-term follow-ups are useful for exploring possible mechanisms and persistence, but they largely return to the same original cohort. They are not independent replications in new populations.
SIRI-HF will test selenium alone
The new SIRI-HF trial is designed to answer a more specific question. It plans to randomize 4,326 adults with diagnosed heart failure in Sweden and Norway to a yeast-based selenium preparation providing 200 µg/day or matching placebo, in addition to standard heart-failure treatment.
Its primary outcome is the total number of recurrent heart-failure hospitalizations and cardiovascular deaths. Recruitment began in April 2026; primary completion is estimated for March 2030, with final completion in March 2031. The public registration does not require low selenium status for enrollment, although a mechanistic substudy will measure selenium-related biomarkers in a subset.
SIRI-HF is therefore important, but it currently proves nothing about benefit. It studies patients who already have heart failure under medical supervision. It should not be used as evidence that healthy people ought to take 200 µg of selenium.
The honest takeaway
Selenium appears to have a narrower useful range than the “more is better” logic of supplement marketing suggests. Baseline status matters. Chemical form matters. Duration matters. And at 200 µg/day or more, this meta-analysis found a lipid response that included higher triglycerides and lower HDL, even though LDL moved in a potentially favorable direction in the dose analysis.
For someone considering a high-dose selenium product, the relevant question is not only whether selenium is essential. It is how much selenium is already coming from food and other supplements, why a high dose is being considered, and whether there is evidence of inadequate status. A supervised clinical-trial dose is not a general nutrition recommendation.
Medical note. This article is for general education and is not personal medical advice. Selenium can be harmful in excessive amounts. Discuss high-dose supplementation with a qualified healthcare professional, particularly if you have a medical condition or use other supplements containing selenium.